Oxford BioMedica to acquire Oxxon Therapeutics

Oxxon Therapeutics is being acquired by Oxford BioMedica, which has been developing gene-based therapeutic vaccines for cancer and neurotherapy. The deal gives the U.K.'s Oxford BioMedica control of Hi-8 MEL, a cancer immunotherapy product that Oxford executives say is complementary to its own late-stage product, TroVax.

"The market opportunity for an effective melanoma vaccine is substantial and this is a cancer type where our immunotherapy, TroVax, cannot be developed because, unlike the vast majority of human tumors, melanomas do not have 5T4 on the surface of the tumor cells," says Oxford CEO Alan Kingsman. "This acquisition is part of the implementation of a plan for the development of our pipeline following finalization of a licensing deal for TroVax."

- see this press release for more
- read the report on the buyout from Science Business

Related Articles:
Oxford BioMedica says licensing talks heating up. Report
BioMedica touts mid-stage Trovax trial data. Report

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.